Form 8-K Celldex Therapeutics, For: Apr 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform
April 16, 2018 1:02 PM EDTCowen downgraded Celldex Therapeutics (NASDAQ: CLDX) from Outperform to Market Perform.
Analyst Boris Peaker commented, "CLDX announced this morning that glemb'a pivotal METRIC study in gpNMB+ TNBC failed to meet its primary PFS endpoint. All glembatumumab development, including checkpoint inhibitor combination in melanoma, will... More
Celldex Therapeutics (CLDX) PT Lowered to $2.50 at H.C. Wainwright
April 16, 2018 10:54 AM EDTH.C. Wainwright lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $2.50 (from $10.00) while maintaining a Buy rating.
Analyst Joseph Pantginis commented, "This morning, Celldex announced that the Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic... More
Celldex (CLDX) Set to Open Lower By 49% After METRIC Study Fails
April 16, 2018 8:24 AM EDTCelldex (NASDAQ: CLDX) was set to open lower by 49% Monday morning after announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.
... More